They haven’t missed any targets. The original IPO listing was...

They haven’t missed any targets. The original IPO listing was scheduled for January and now the compliance listing will be February. There are significant advantages to this change for shareholders and it’s been well articulated by the CEO.

Have you looked at the NASDAQ and the Biotech Index recently?

Why would the company raise capital in the US under those conditions when they have $20 million in the bank and can achieve a NASDAQ listing without taking discounted money from new US investors. That’s common sense and positive for shareholders.

As they stated, when conditions improve they have the flexibility to raise capital at a future point in time and quite possibly at much higher prices if the current trend of clinical results continue.

This is sound capital management and I’ve been in plenty of stocks where the board just takes the money and shareholders get chopped up. This isn’t one of those companies and it’s one of the reasons why I bought more stock after that AGM.